Visfatin is not associated with inflammatory markers in patients on hemodialysis

Clinical Laboratory

Volumn 59, Issue 11-12, 2013, Pages 1253-1259

  Celap, Ivana ^a   Simundic, Ana Maria ^a   Nikolac, Nora ^a   Miler, Marijana ^a   Zec, Ivana ^a   Altabas, Karmela ^a   Sefer, Sinisa ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Endothelial dysfunction; Fibrinogen; Hemodialysis; Inflammation; PAI 1; Visfatin

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; COLECALCIFEROL; FIBRINOGEN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SEX HORMONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; STANDARD; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENAL DIALYSIS;

EID: 84891591155     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2013.121036     Document Type: Article

References (30)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69. (Pubitemid 37337595)
2. Norata GD, Baragetti I, Raselli S, et al. Plasma adiponectin levels in chronic kidney disease patients: Relation with molecular inflammatory profile and metabolic status. Nutr Metab Cardiovasc Dis 2010;20:56-63.
3. Segara A, Chacon P, Martinez-Eyarre C, et al. Circulating Levels of Plasminogen Activator Inhibitor Type-1, Tissue Plasminogen Activator, and Thrombomodulin in Hemodialysis Patients: Biochemical Correlations and Role as Independent Predictors of Coronary Artery Stenosis. J Am Soc Nephrol 2001;12:1255-63. (Pubitemid 32472640)
4. Ziegelmeier M, Bachman A, Seeger J, et al. Adipokines influencing metabolic and cardiovascular disease are differentially regulated in maintanance hemodialysis. Metabolism 2008;57:1414-21.
5. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin. Science 2005;307:426-30. (Pubitemid 40139988)
6. Curat CA, Wenger V, Senegenes C, Miranville A, Tonus C, Busse R: Macrophages in human visceral adipose tissue.increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006;49:744-7. (Pubitemid 43357549)
7. Varma V, Yao-Borengasser A, Rasouli N, et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids and inflammation. J Clin Endocrinol Metab 2007;92:666-72.
8. Zoccali C. Endothelial dysfunction in CKD: a new player in town? Nephrol Dial Transplant 2008;23:783-5. (Pubitemid 351767596)
9. Ye SQ, Simon BA, Maloney JP, et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Resp Crit Care Med 2005;171:361-70. (Pubitemid 40223404)
10. Aller R, de Luis DA, Izaola O, et al. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci 2009;54:1772-7.
11. Romaco T, Azcutia V, Vazquez-Bella M, et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signaling in human vascular smooth cell muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 2009;52:2455-63.
12. Yilmaz MI, Saglam M, Carrero JJ, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008;23:959-65. (Pubitemid 351767576)
13. Malyszko J, Malyszko JS, Mysliwiec M. Visfatin, a New Adipocytokine, Is Predominantly Related to Inflammation/Endothelial Damage in Kidney Allograft Recipients. Transplant Proc 2009;141:150-3.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
15. Pupovac V, Petrovecki M. Summarizing and presenting numerical data. Biochem Med 2011;21:106-10.
16. Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation but not with insulin resistance. Clin Endocrin 2007;67:796-800. (Pubitemid 47628470)
17. Axelsson J, Witasp A, Carrero A, et al. Circulating Levels of Visfatin/Pre-B-Cell Colony-Enhancing Factor 1 in Relation to Genotype, GFR, Body Compostion, and Survival in Patients With CKD. Am J Kidney Dis 2007;49:237-44. (Pubitemid 46178402)
18. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci 2008;53:32-6.
19. Derosa G, Maffioli P, Ferrari I, et al. Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertension Research 2011;34:145-51.
20. Margetic S. Inflammation and hemostasis. Biochem Med 2012;22:49-62.
21. Tomura S, Nakamura Y, Doi M, et al. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1996;27:848-54. (Pubitemid 26169038)
22. Sabovic M, Salobir B, Preloznik Zupan I, et al. The influence of the hemodialysis procedure on platelets, coagulation and fibrinolysis. Pathophysiol Haemost Thromb 2005;34:274-8. (Pubitemid 43882426)
23. Milburn JA, Cassar K, Ford I, Fluck N, Brittenden J. Prothrombotic changes in platelet, endothelial and coagulation function follow ing hemodialysis. Int J Artif Organs 2011;34:280-7.
24. Reimann M, Ziemssen T, Huisman HW, et al. Ethnic-specific correlations of visfatin with circulating markers of endothelial inflammation and function. Obesity 2009;17:2210-5.
25. Kato A, Odamaki M, Ishida J, Hishida A. Relationship between scrum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am J Nephrol 2008;29:31-5.
26. Malyszko J, Malyszko JS, Mysliwiec M. Visfatin and endothelial dysfunction in dialysed patients. Nephrology 2010;15:190-6.
27. Bai J, Liu Y, Niu GF, et al. Relationship between adiponectin and testosterone in patients with type 2 diabetes. Biochemia Medica 2011;21:65-70.
28. Peng Y, Liu H, Liu F, et al. Atherosclerosis is associated with plasminogen activator inhibitor type-1 in chronic haemodialysis patients. Nephrology 2008;13:579-86.
29. Irish AB. Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis. Metabolism 1997;46:36-40. (Pubitemid 27052021)
30. Fogari R, Mugellini A, Zoppi A, et al. Losartan and Perindopril Effects on Plasma Plasminogen Activator Inhibitor-1 and Fibrinogen in Hypertensive Type 2 Diabetic Patients. Am J Hypertens 2002;15:316-20. (Pubitemid 34408970)